- Report
- March 2025
- 193 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- October 2024
- 199 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2024
- 336 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- October 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
Dermatophytic Onychomycosis (DO) is a fungal infection of the nail caused by dermatophytes. It is the most common type of onychomycosis, accounting for up to 50% of all nail infections. Treatment of DO typically involves the use of antifungal drugs, such as terbinafine, itraconazole, and fluconazole. These drugs are typically administered orally or topically, depending on the severity of the infection.
Infectious Diseases Drugs are a class of drugs used to treat a wide range of infectious diseases, including DO. These drugs are typically prescribed by a physician and are available in both generic and brand-name formulations. Commonly prescribed Infectious Diseases Drugs include antibiotics, antivirals, antifungals, and antiparasitics.
Some companies in the Dermatophytic Onychomycosis Drug market include Pfizer, Merck, Novartis, and Johnson & Johnson. Show Less Read more